SWOG S1203

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia



A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

S1203 is fast-approaching its accrual goal and will permanently close to accrual effective November 4, 2015 at 11:59 pm Pacific Time.


Leave a Reply